These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 8854570

  • 1. Changes in factor VIII binding capacity of von Willebrand factor and factor VIII coagulant activity in two patients with type 2N von Willebrand disease after hemostatic treatment and during pregnancy.
    Nishino M, Nishino S, Sugimoto M, Shibata M, Tsuji S, Yoshioka A.
    Int J Hematol; 1996 Aug; 64(2):127-34. PubMed ID: 8854570
    [Abstract] [Full Text] [Related]

  • 2. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G, Federici AB, Bernardi M, Moroni B, Bertoncello K, Rodeghiero F.
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [Abstract] [Full Text] [Related]

  • 3. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 4. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
    Miller CH, Kelley L, Green D.
    Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
    [Abstract] [Full Text] [Related]

  • 5. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M, Simoni L, Gringeri A, Mannucci PM.
    Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
    [Abstract] [Full Text] [Related]

  • 6. Biological effect of desmopressin in eight patients with type 2N ('Normandy') von Willebrand disease. Collaborative Group.
    Mazurier C, Gaucher C, Jorieux S, Goudemand M.
    Br J Haematol; 1994 Dec; 88(4):849-54. PubMed ID: 7819109
    [Abstract] [Full Text] [Related]

  • 7. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 Dec; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

  • 8. The effects of desmopressin on plasma factor VIII/von Willebrand factor activity in dogs with von Willebrand's disease.
    Johnstone IB, Crane S.
    Can J Vet Res; 1987 Apr; 51(2):189-93. PubMed ID: 3111674
    [Abstract] [Full Text] [Related]

  • 9. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
    López-Fernández MF, Blanco-López MJ, Castiñeira MP, Batlle J.
    Am J Hematol; 1992 May; 40(1):20-7. PubMed ID: 1566742
    [Abstract] [Full Text] [Related]

  • 10. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 May; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 11. [Diagnosis and management of von Willebrand disease].
    Higasa S, Tokugawa T, Sawada A.
    Rinsho Ketsueki; 2018 May; 59(10):2222-2232. PubMed ID: 30305529
    [Abstract] [Full Text] [Related]

  • 12. The Course of von Willebrand Factor and Factor VIII Activity in Patients with von Willebrand Disease during Pregnancy.
    Delbrück C, Miesbach W.
    Acta Haematol; 2019 May; 142(2):71-78. PubMed ID: 31085919
    [Abstract] [Full Text] [Related]

  • 13. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [Abstract] [Full Text] [Related]

  • 14. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
    Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A.
    Am J Clin Pathol; 1998 Mar; 109(3):347-52. PubMed ID: 9495210
    [Abstract] [Full Text] [Related]

  • 15. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL, Georgescu I, Mewburn J, Deforest M, Nesbitt K, Hebert K, Dwyer C, Brown C, Notley C, Lillicrap D.
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [Abstract] [Full Text] [Related]

  • 16. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
    Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M.
    Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
    [Abstract] [Full Text] [Related]

  • 17. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
    Castaman G, Lattuada A, Mannucci PM, Rodeghiero F.
    Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
    [Abstract] [Full Text] [Related]

  • 18. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA.
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [Abstract] [Full Text] [Related]

  • 19. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ, van Vliet HH.
    Acta Haematol; 2009 Mar; 121(2-3):154-66. PubMed ID: 19506362
    [Abstract] [Full Text] [Related]

  • 20. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ, van Vliet HH, Berneman Z, Schroyens W, Gadisseur A.
    Acta Haematol; 2009 Mar; 121(2-3):167-76. PubMed ID: 19506363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.